Hamartoma Syndrome, Multiple clinical trials

The registry lists 21 studies for Hamartoma Syndrome, Multiple across more than 10 countries. 9 are recruiting or about to start. 9 of them are mainly about Hamartoma Syndrome, Multiple (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29.

Get an email when these change. Save the Hamartoma Syndrome, Multiple studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 8
Completed: 8
Active, not recruiting: 2
Not yet recruiting: 1
Withdrawn: 1
Status unknown: 1

Phase

Phase 2: 6
Phase 1: 4
Phase 3: 1

Where

United States: 13
United Kingdom: 5
Spain: 3
Canada: 3
Italy: 1
Germany: 1

Who runs them

Boston Children's Hospital (3) · Royal Marsden NHS Foundation Trust (2) · Novartis Pharmaceuticals (2) · National Cancer Institute (NCI) (2) · Yale University (1) · St. Jude Children's Research Hospital (1) · University Health Network, Toronto (1) · Ohio State University (1)

What is being tested here

Drugs under test in Hamartoma Syndrome, Multiple studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Everolimus	1	1	2
Sirolimus	0	0	3
Dactolisib	0	0	1

Drug classes tested here mTOR inhibitors 1 open

Coming up

1phase 3 study under way

4studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4

Dec 2026Web Intervention for Parents of Youth With Genetic Syndromes (WINGS) · Rush University Medical Center
Dec 2026PTEN Hamartoma Tumor Syndrome Pediatric Patient Registry · Yale University
Feb 2027Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer · Sir Mortimer B. Davis - Jewish General Hospital
Jul 2027Liquid Biopsy Evaluation and Repository Development at Princess Margaret · University Health Network, Toronto

Who these studies take

Of the 8 Hamartoma Syndrome, Multiple studies recruiting now, 6 (75%) set no upper age limit and 1 (13%) stop at 75 or younger. 3 (38%) take children under 18. 1 (13%) are for women only and 0 (0%) for men only; 3 (38%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	3 (38%)	3 (38%)
18	7 (88%)	6 (75%)
30	7 (88%)	6 (75%)
40	7 (88%)	6 (75%)
50	7 (88%)	6 (75%)
65	7 (88%)	6 (75%)
75	7 (88%)	6 (75%)
85	7 (88%)	6 (75%)

Across all 21 studies, recruiting or not: 29% stop at 75 or younger and 29% at 65; 43% take children; 5% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 21 of 21. search them.